RECURSION LONDON LTD

12648333
Active Altrincham

Research and experimental development on biotechnology

11 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
R

RECURSION LONDON LTD

12648333

Research and experimental development on biotechnology

Founded 5 Jun 2020 Active Altrincham, United Kingdom 11 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

CYCLICA LTD 5 Jun 2020 — 26 Mar 2024
Accounts Submitted 2 Jan 2026 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 12 Jun 2025 Next due 18 Jun 2026 2 days overdue
Net assets £188K £573K 2024 year on year
Total assets £4M
Total Liabilities £3M £3M 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kingdom

Website

www.example.com

Full company profile for RECURSION LONDON LTD (12648333), an active life sciences and medical technology company based in Altrincham, United Kingdom. Incorporated 5 Jun 2020. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type small
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Balance Sheet & P&L (2020–2024)

Cash in Bank

£653.33k

Net Assets

£188.02k

Increased by £573.13k (+149%)

Total Liabilities

£3.47M

Increased by £3.09M (+802%)

Turnover

£4.87M

Employees

11

Increased by 10 (+1000%)

Debt Ratio

95%

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (2)

Recursion Pharmaceuticals, Inc
100.0%
1
Cyclica Therapeutics Inc
0.0%
0

Persons with Significant Control

Persons with Significant Control (1)

1 Active

Recursion Pharmaceuticals, Inc.

United States Of America

Active
Notified 25 May 2023
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

Group Structure

Group Structure

RECURSION LONDON LTD Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
19 May 2026OfficersTermination of Christopher Cory Gibson as director on 15 May 2026
19 May 2026OfficersAppointment of Andrew John Overton as director on 15 May 2026
19 May 2026OfficersAppointment of Kyle Benjamin Nelson as director on 15 May 2026
19 May 2026OfficersTermination of Nathan Ben Hatfield as director on 15 May 2026
2 Jan 2026AccountsAnnual accounts made up to 31 Dec 2024
19 May 2026 Officers

Termination of Christopher Cory Gibson as director on 15 May 2026

19 May 2026 Officers

Appointment of Andrew John Overton as director on 15 May 2026

19 May 2026 Officers

Appointment of Kyle Benjamin Nelson as director on 15 May 2026

19 May 2026 Officers

Termination of Nathan Ben Hatfield as director on 15 May 2026

2 Jan 2026 Accounts

Annual accounts made up to 31 Dec 2024

Recent Activity

Latest Activity

Termination of Christopher Cory Gibson as director on 15 May 2026

1 months ago on 19 May 2026

Appointment of Andrew John Overton as director on 15 May 2026

1 months ago on 19 May 2026

Appointment of Kyle Benjamin Nelson as director on 15 May 2026

1 months ago on 19 May 2026

Termination of Nathan Ben Hatfield as director on 15 May 2026

1 months ago on 19 May 2026

Annual accounts made up to 31 Dec 2024

5 months ago on 2 Jan 2026